Pharmacovigilance Market By Drug Development (Preclinical Studies, Phase I, Phase II, Phase III, Phase IV Or Post Marketing Surveillance), By Reporting Methods (Spontaneous Reporting, Intensified Adr Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, Ehr Mining), By Services (In-house, Contract Outsourcing) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2022

Market Insights:

Exaggerating regulatory compliance, efficient maintenance of product life cycle, and the growing need for prompt patient reporting have boosted the need for pharmacovigilance. Pharmaceutical companies are increasingly entering into long-term arrangements with CROs and BPOs for performing pharmacovigilance activities initiating from the drug discovery phase to post-market surveillance.

This report studies the global pharmacovigilance market based on clinical trial phases, reporting methods, service methods, and geography. In terms of clinical trial phases, this market is studied for pharmacovigilance in preclinical studies, phase I trial, phase II trial, phase III trial, and phase IV. Spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining is the reporting methods analyzed in this report. Additionally, In-House pharmacovigilance and contract outsourcing are the pharmacovigilance services considered in this study. North America, Europe, Asia-Pacific, the Middle East, North Africa, and Latin America are the regional markets cumulatively making the global pharmacovigilance market. This section also includes a country-level analysis of the national markets that hold major hold in the respective regional markets.

Market estimations and forecasts for 2014 to 2022 are provided in this report for all the mentioned segments along with their respective Compounded Annual Growth Rate (CAGR %) for the period 2016-2022 while considering 2015 as the base year.

Along with the quantitative information sets, this report also provides qualitative market assessment information such as market dynamics: drivers, challenges, and prospects. This report includes competition assessment tools such as attractive investment proposition and fractal map analysis for analyzing the market competition. This study concludes with a company profiles section highlighting key information about the major players operating in the global pharmacovigilance market. In-house pharmacovigilance and contract outsourcing are the two pharmacovigilance services adopted by pharmaceutical companies. The pharmacovigilance process is often outsourced to contract outsourcing companies, and it is anticipated that the same trend will continue through the forecast period.

The contract outsourcing segment takes over half the market share and is anticipated to progress at a faster CAGR than in-house pharmacovigilance. Contract outsourcing is a faster and cost-effective option; the CROs resourced are valued in the market for their core expertise in the respective processes. Furthermore, featured advantages such as reduction in overhead expenditures, focusing on core competencies, and workforce streamlining also have been urging pharmaceutical companies to opt for contract outsourcing. In-house pharmacovigilance systems will remain in practice, majorly opted by large pharmaceutical companies for their high-profile drugs and small players for cost containment purposes.

Among the mentioned segments, phase IV or post-market reporting took the largest market share in 2015. This stage is characterized by a prompt collection of post-market development, adverse events, and examination and monitoring of associated hazards. Growth in the number of novel drugs being introduced in the market has necessitated the need for post-marled surveillance, thus propelling the phase IV pharmacovigilance segment. In addition, the necessity for risk assessment studies during late-stage drug development, the decision on precise medication, and the establishment of safety data are the prime factors that constitute the rapid market growth of the phase III pharmacovigilance segment.

North America, Europe, Asia Pacific, Middle East, Africa, and Latin America together make for the global pharmacovigilance market.

North America is the largest regional market for pharmacovigilance processes. The dominance of North America is majorly attributed to growth in clinical research activities in the region. The U.S. is the largest country-level market for pharmacovigilance due to many research units and pharmaceutical companies. The regulatory framework demanding strict compliance from pharmaceutical companies in the U.S. is also a contributing factor to the large-scale pharmacovigilance activities in the country. Asia-Pacific countries such as Japan, Korea, Australia, and others are undergoing rapid growth in the pharmacovigilance market; outsourcing clinical activities to south Asia plays a critical role in the Asia-Pacific market.

The detailed classification of the global pharmacovigilance market is as follows:

• North America (U.S. & Canada)
• Europe (U.K., Germany, and Rest of Europe)
• Asia-Pacific (Japan, China, and Rest of Asia-Pacific)
• The Middle East and Africa
• Latin America

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Pharmacovigilance Market Share, by Drug Development Phase, 2015 (Value %)
2.2 Pharmacovigilance Market, by Methods, 2014-2022 (USD Mn)
2.3 Pharmacovigilance Market, by Services, 2014-2022 (USD Mn)
2.4 Pharmacovigilance Market Share, by Geography, 2015 (Value %)

Chapter 3 Pharmacovigilance Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Drivers
3.3 Challenges
3.4 Future Prospects
3.5 Attractive Investment Proposition
3.1 Competitive Analysis: Fractal Map Investigation, by Key Market Players

Chapter 4 Global Pharmacovigilance Market Analysis, by Drug Development Phase
4.1 Preface
4.2 Preclinical Studies
4.3 Phase I
4.4 Phase II
4.5 Phase III
4.6 Phase IV or Post Marketing Surveillance

Chapter 5 Global Pharmacovigilance Market Analysis, by Reporting Methods
5.1 Preface
5.2 Spontaneous Reporting
5.3 Intensified ADR Reporting
5.4 Targeted Spontaneous Reporting
5.5 Cohort Event Monitoring
5.6 EHR Mining

Chapter 6 Global Pharmacovigilance Market Analysis, by Services
6.1 Preface
6.2 In-house
6.3 Contract Outsourcing

Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Preface
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Middle East and Africa (MEA)
7.6 Latin America

Chapter 8 Company Profiles
8.1 Accenture Plc.
8.1.1 Business Description
8.1.2 Financial Health and Budget Allocation
8.1.3 Product Positions/Portfolio
8.1.4 News Coverage
8.2 Bristol-Myers Squibb
8.2.1 Business Description
8.2.2 Financial Health and Budget Allocation
8.2.3 Product Positions/Portfolio
8.2.4 News Coverage
8.3 Clinquest Group B.V.
8.3.1 Business Description
8.3.2 Financial Health and Budget Allocation
8.3.3 Product Positions/Portfolio
8.3.4 News Coverage
8.4 Cognizant Technology Solutions
8.4.1 Business Description
8.4.2 Financial Health and Budget Allocation
8.4.3 Product Positions/Portfolio
8.4.4 News Coverage
8.5 Covance, Inc.
8.5.1 Business Description
8.5.2 Financial Health and Budget Allocation
8.5.3 Product Positions/Portfolio
8.5.4 News Coverage
8.6 F. Hoffmann-La Roche Ltd.
8.6.1 Business Description
8.6.2 Financial Health and Budget Allocation
8.6.3 Product Positions/Portfolio
8.6.4 News Coverage
8.7 GSK
8.7.1 Business Description
8.7.2 Financial Health and Budget Allocation
8.7.3 Product Positions/Portfolio
8.7.4 News Coverage
8.8 ICON plc
8.8.1 Business Description
8.8.2 Financial Health and Budget Allocation
8.8.3 Product Positions/Portfolio
8.8.4 News Coverage
8.9 iGATE Corporation
8.9.1 Business Description
8.9.2 Financial Health and Budget Allocation
8.9.3 Product Positions/Portfolio
8.9.4 News Coverage
8.10 iMEDGlobal Corporation
8.10.1 Business Description
8.10.2 Financial Health and Budget Allocation
8.10.3 Product Positions/Portfolio
8.10.4 News Coverage
8.11 inVentiv Health, Inc.
8.11.1 Business Description
8.11.2 Financial Health and Budget Allocation
8.11.3 Product Positions/Portfolio
8.11.4 News Coverage
8.12 PAREXEL International Corporation
8.12.1 Business Description
8.12.2 Financial Health and Budget Allocation
8.12.3 Product Positions/Portfolio
8.12.4 News Coverage
8.13 PRA Health Sciences, Inc.
8.13.1 Business Description
8.13.2 Financial Health and Budget Allocation
8.13.3 Product Positions/Portfolio
8.13.4 News Coverage
8.14 Quintiles Transnational Holdings, Inc.
8.14.1 Business Description
8.14.2 Financial Health and Budget Allocation
8.14.3 Product Positions/Portfolio
8.14.4 News Coverage
8.15 Synowledge LLC
8.15.1 Business Description
8.15.2 Financial Health and Budget Allocation
8.15.3 Product Positions/Portfolio
8.15.4 News Coverage
8.16 Wipro Limited
8.16.1 Business Description
8.16.2 Financial Health and Budget Allocation
8.16.3 Product Positions/Portfolio
8.16.4 News Coverage
8.17 Others

 

List of Figures

FIG. 1 Pharmacovigilance: Market Segmentation
FIG. 2 Pharmacovigilance Market Share, by Drug Development Phase, 2015 (Value %)
FIG. 3 Pharmacovigilance Market, by Methods, 2014-2022 (USD Mn)
FIG. 4 Pharmacovigilance Market, by Services, 2014-2022 (USD Mn)
FIG. 5 Pharmacovigilance Market Share, by Geography, 2015 (Value %)
FIG. 6 Attractive Investment Proposition, Pharmacovigilance Market, 2015
FIG. 7 Competitive Analysis: Fractal Map Investigation, by Key Market Players
FIG. 8 Global Preclinical Studies Market, 2014 – 2022 (USD Mn)
FIG. 9 Global Phase I Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 10 Global Phase I Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 11 Global Phase III Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 12 Global Phase IV or Post Marketing Surveillance Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 13 Global Spontaneous Reporting Market, 2014 – 2022 (USD Mn)
FIG. 14 Global Intensified ADR Reporting Market, 2014 – 2022 (USD Mn)
FIG. 15 Global Targeted Spontaneous Reporting Market, 2014 – 2022 (USD Mn)
FIG. 16 Global Cohort Event Monitoring Market, 2014 – 2022 (USD Mn)
FIG. 17 Global EHR Mining Market, 2014 – 2022 (USD Mn)
FIG. 18 Global In-House Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 19 Global Contract Outsourcing Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 20 U.S. Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 21 Canada Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 22 U.K. Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 23 Germany Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 24 Rest of Europe Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 25 Japan Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 26 China Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 27 Rest of Asia-Pacific Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 28 Middle East and Africa Pharmacovigilance Market, 2014 – 2022 (USD Mn)
FIG. 29 Latin America Pharmacovigilance Market, 2014 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Pharmacovigilance Market, by Drug Development Phase, 2014 – 2022 (USD Mn)
TABLE 2 Global Pharmacovigilance Market, by Reporting Methods, 2014 – 2022 (USD Mn)
TABLE 3 Global Pharmacovigilance Market, by Services, 2014 – 2022 (USD Mn)
TABLE 4 Global Pharmacovigilance Market, by Geography, 2014 – 2022 (USD Mn)
TABLE 5 North Pharmacovigilance Market, by Country, 2014 – 2022 (USD Mn)
TABLE 6 Europe Pharmacovigilance Market, by Country, 2014 – 2022 (USD Mn)
TABLE 7 Asia-Pacific Pharmacovigilance Market, by Country, 2014 – 2022 (USD Mn)